Boston, MA 05/02/2014 (wallstreetpr) – One of the leading research leaders, Gilead Sciences, Inc. (NASDAQ:GILD) operates in the biopharmaceutical sector for commercialization and development of medicines. The company is working towards creating innovative changes in facilitating the treatment of AIDS, Hepatitis and other diseases. Recently the company has released significant drugs in the market that have proved to be a boon in the treatment of deadly diseases like hepatitis and AIDS in an effective manner. Gilead is also progressing towards investing in its research and development activity for development of other breakthrough discoveries.
More Advanced Cure for Hepatitis C
Gilead Sciences, Inc. (NASDAQ:GILD) has recently released a new drug called Sovaldi that has created a revolution in the treatment of hepatitis C. Vice President of Gilead, Gregg Alton recently said that Sovaldi has led to effective treatment of hepatitis C leading, and further has significantly contributed in reducing the cost of the drug. Gilead highlights that the old therapies cost around $150k-$200k involving longer treatments. However the new treatment with Sovaldi helps in the treatment of hepatitis C in just three months at $1000/ day.
FDA clearance for Gilead
Gilead Sciences recently declared that the FDA has accepted its proposal of refilling of two of its New Drug Applications. The applications were related to cobicistat – a boosting agent for increasing blood levels of the protease inhibitors. This in turn helps in effective treatment of adults suffering from HIV infection. Food and Drug Association has fixed dates for target review under the PDUF Act.
The date narrowed by the company is October 3, 2014 for Cobicistat and October 4, 204 for elvitegravir that helps in the treatment of patients infected by HIV-1 infection. Both Cobicisat and elvitegravir are part of Gilead’s Stribild®. Gilead submitted the plans for both significant drugs in the year 2012 and received response letters from Food and Development Authority in the year 2013. Gilead Sciences, Inc. (NASDAQ:GILD)s is all set for innovating new treatment drugs on the same that can be both cost effective and highly efficient.
